Holen Sie sich die Stockscreener-App
17.43
1.93%
0.33
Handel nachbörslich:
17.69
0.26
+1.49%
Schlusskurs vom Vortag:
$17.10
Offen:
$17.45
24-Stunden-Volumen:
530.55K
Relative Volume:
0.52
Marktkapitalisierung:
$1.07B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-221.04M
KGV:
-4.6927
EPS:
-3.7143
Netto-Cashflow:
$-178.65M
1W Leistung:
-0.40%
1M Leistung:
-5.27%
6M Leistung:
+41.25%
1J Leistung:
+113.08%
1-Tages-Spanne:
$17.13
$17.99
1-Wochen-Bereich:
$17.06
$18.23
52-Wochen-Spanne:
$5.68
$19.43
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
17.43 | 1.05B | 0 | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Eingeleitet | Citigroup | Buy |
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-08-21 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-06-11 | Fortgesetzt | Stifel | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Cullinan Therapeutics Inc (CGEM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CGEM|Cullinan Therapeutics Inc|Price:17.775|Chg%:+0.675 - TradingKey
Cullinan Therapeutics Inc (CGEM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cullinan Therapeutics Inc (CGEM) Institutional Confidence - TradingKey
TradingKey - TradingKey
ETFs Investing in Cullinan Therapeutics, Inc. Stocks - TradingView
CGEM|Cullinan Therapeutics Inc|Price:17.700|Chg%:+0.600 - TradingKey
Cullinan Therapeutics Inc (CGEM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cullinan Therapeutics Inc (CGEM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cullinan Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGEM - TradingView
Cullinan Therapeutics Inc (CGEM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cullinan Therapeutics (CGEM) Edges Higher as Modest Gains Signal Steady SentimentMACD Signal Stocks - dars.gov.et
Cullinan CSO sells shares, exercises options | CGEM Insider Trading - Stock Titan
Enterprise value to EBIT forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
Price to sales forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
CGEM (NASDAQ) insider resale notice: 8,000 shares proposed, prior 10b5-1 sales noted - Stock Titan
Enterprise value to revenue forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
Price to earnings forward of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
CGEMCullinan Therapeutics Inc Latest SEC Filings - Finviz
Cullinan Therapeutics (CGEM) CFO adds 1,541 shares through ESPP purchase - Stock Titan
Cullinan Therapeutics (CGEM) CLO adds 2,470 ESPP shares at $8.60 - Stock Titan
EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innovative Medicine - Barchart.com
Cullinan Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGEM) - TradingView
CGEM Forecast — Price Target — Prediction for 2027 - TradingView
Cullinan Therapeutics (CGEM) Is Up 31.0% After Autoimmune T Cell Engager Data – Has The Bull Case Changed? - Sahm
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com - Investing.com Australia
Cullinan Oncology stock hits 52-week high at $17.97 - Investing.com UK
Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes - Yahoo Finance
Cullinan Therapeutics Inc (CGEM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cullinan Therapeutics (CGEM) Citi’s 2026 Virtual Oncology Leadership Summit Summary - Quartr
Cullinan Therapeutics (CGEM) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Cullinan Therapeutics (CGEM) Surges 4%: Key Levels to Watch After Recent UptickOpening Range Breakout - dars.gov.et
CULLINAN THERAPEUTICS INC (CGEM) Stock Chart - ChartMill
Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant - Stock Titan
Cullinan Therapeutics (CGEM) grants director 25,319 stock options - Stock Titan
Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM) - Stock Titan
Cullinan Therapeutics (CGEM) director receives stock options for 25,319 shares - Stock Titan
Cullinan Therapeutics (CGEM) grants director Mittie Doyle 21,781 stock options - Stock Titan
Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike - Stock Titan
Cullinan Therapeutics Inc (CGEM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cullinan Therapeutics Inc (CGEM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cullinan Therapeutics shareholders elect directors and approve proposals at annual meeting - Investing.com
Cullinan Therapeutics (NASDAQ: CGEM) shareholders back directors, KPMG and pay - Stock Titan
Cullinan Therapeutics (CGEM) Edges Lower, Testing Key Support Zone Amid Sector VolatilityEntry Point Alerts - DonanımHaber
Cullinan Therapeutics CSO to join MITCEO Conference panel on advancing patient medicines - Traders Union
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and Viridian Therapeutics (VRDN) - The Globe and Mail
CGEM Reiterated by Wedbush -- Price Target Maintained at $37 - GuruFocus
Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM) - Seeking Alpha
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):